Background: The expression of oestrogen receptor (ER) a characterises a subset of breast cancers associated with good response to endocrine therapy. However, the clinical significance of the second ER, ERb1, and its splice variant ERbcx is still unclear.
indicate partly overlapping transcriptomes induced by the two ER subtypes (Chang et al, 2006) . However, experimental studies in vitro and during tumour xenograft growth have shown opposing roles of the two receptors in terms of proliferation (Ström et al, 2004; Hartman et al, 2006) . Contributing to the complex picture of ERb signalling is the presence of several splice variants. The full-length ERb is known as ERb1 whereas the best characterised splice variant in breast cancer is ERbcx (also known as ERb2; Ogawa et al, 1998) . We now know that ERb is expressed in the epithelium and stroma of normal as well as malignant mammary gland and mediates oestrogen response. Immunohistochemistry (IHC) studies indicate an association of ERb expression with ERa-positive tumours and/or progesterone receptor (PR) status (Omoto et al, 2002; Fuqua et al, 2003) . However, these studies were in part performed with pan-specific antibodies detecting all ERb splice variants, including ERbcx. Later on, the roles of different ERb splice variants have been dissected by the use of monoclonal C-terminus-targeted ERb antibodies. It now appears that ERb expression is associated with tamoxifen response, particularly within ERa-negative tumours (Gruvberger-Saal et al, 2007; Honma et al, 2008) . Other researchers have been unable to confirm this association and instead report an association between ERbcx and ERa expression and a strong correlation of cytoplasmic ERbcx with poor survival (Shaaban et al, 2008) . In a large populationbased study, Marotti et al (2009) could confirm a positive correlation of ERb1 expression with ERa, but not with survival; similar results were described by Borgquist et al (2008) . One study has even shown an association of ERb1 with poor prognosis, but only in lymph nodepositive patients (Novelli et al, 2008) . The majority of studies on larger patient populations have been performed by IHC on tissue microarrays (TMAs), a suboptimal platform for investigating heterogeneously expressed proteins. In the present study, we characterised ERb1 and ERbcx and re-evaluated ERa expression by IHC of whole tumour sections from 340 patients with archived breast tumours and corresponding sentinel lymph nodes (SLNs).
MATERIALS AND METHODS
Study population and follow-up. The study cohort was identified from the patient registry at the Department of Pathology, Karolinska University Hospital, Stockholm, Sweden. Only patients who had undergone sentinel node biopsy (SNB) from 2001 to 2006 were included. All patients had a preoperative diagnosis of breast cancer and a clinically negative axilla. A subset of the cohort originated from a prospective study evaluating the oncological safety of SNB, the results of which have been published elsewhere (Andersson et al, 2012) . The surgery was performed at either Karolinska University Hospital, South General Hospital or at Sofiahemmet Hospital, all in the Stockholm area. Routinely, patients were followed up annually for 5-10 years, and then reintroduced into the national mammography-screening programme. All recurrences within the Stockholm area are routinely referred back to the Department of Oncology at Karolinska University Hospital where the study has been performed. Patients who had moved away from the Stockholm County during followup were censored at the time of their deregistration.
Clinicopathological parameters and data on received adjuvant therapy were extracted from patient medical records. As some of the routine assessments such as PR and proliferation markers changed during the period, cut-offs employed at the time of diagnosis were used. Oestrogen receptor a was because if its central role in this study, however, re-evaluated throughout using IHC. Depending on tumour characteristics and stage of the disease, patients were treated with radiotherapy, chemotherapy and/or endocrine therapy. The occurrence of local, regional or distant relapse, death, breast cancer-specific death and the dates of last follow-up were collected by assessing the medical records of each patient. Permits were obtained from the regional ethics board at Karolinska Institutet in Stockholm (2012/90-31/2) and from the biobank at Karolinska University Hospital.
Specimen selection and immunohistochemistry. From each patient, one formalin-fixed paraffin tissue block of the primary tumour and one block of the matching SLN were identified. The sections were cut at 4-mm thickness and mounted. Immunohistochemistry was performed either on an Autostainer (Dako, Glostrup, Denmark; ERb1) or on IntelliPath FLX (BioCare medical, Concord, CA, USA; ERa and ERbcx) according to the protocols and reagents provided by the manufacturers (BioCare medical and Dako), together with negative and positive controls. Heat-induced antigen retrieval in high pH solution was performed using a PT-linker (Dako) at 971C for 20 min. The slides were incubated for 30 min at room temperature with the primary monoclonal antibodies. Anti-ERb1 (clone PPG5/10; Dako) 1 : 50, anti-ERbcx (clone 57/3; AbD Serotec, Oxford, UK) 1 : 200 and anti-ERa (clone NCL-L-ER-6F11; Novocastra, Wetzlar, Germany) 1 : 200 antibodies were used. 3,3 0 -diaminobenzidine (DAB) was used to detect primary antibody binding and haematoxylin as counterstaining.
Digitalisation of slides and image analysis. To set appropriate intensity cut-offs for the digital scoring, a subset of tumours and SLNs were first scored manually by two independent researchers for ERa, ERb1 (GR and JH) and ERbcx (GR and GMK) in the following compartments: primary tumour, SLN metastasis, if present, and lymphocytes residing in the SLN. The Allred scoring system was used for the manual scoring. The method has been adapted to evaluate and quantify different proteins using IHC (Fuqua et al, 2003; Rosin et al, 2012) . When the two researchers did not agree on the score, they re-evaluated the section together until an agreement could be reached. All slides were digitally scanned using a Pannoramic MIDI or Pannoramic 250 Flash (3DHistech, Budapest, Hungary). The Pannoramic viewer 1.15.2 software (3DHistech) was used for viewing the scanned images together with the built-in image analysis application, Nuclear-Quant (3DHistech), which has been validated and shown to be reproducible in the detection of ER in breast cancer (Krecsák et al, 2011) . The software quantifies both the frequency and intensity of nuclear staining with DAB. Detection thresholds for the size, circularity and differences in contrast of the nuclei can be adjusted to distinguish cancer cells from other cell types such as fibroblasts or lymphocytes. The frequency score was based on the Allred system (Harvey et al, 1999) , where a score between 0 and 5 is given depending on the frequency of positive cells (0% ¼ 0, o1% ¼ 1, 1% to o10% ¼ 2, 10% to o33% ¼ 3, 33% to o66% ¼ 4 and X66% ¼ 5). The cut-off for the intensity (0 to 255) can also be changed to adjust the threshold to divide the nuclei stained into four different scoring categories ('no positive nuclei' ¼ 0, 'low intensity' ¼ 1, 'moderate intensity' ¼ 2 and 'high intensity' ¼ 3). The cut-offs were adjusted in a stepwise manner until the manual scoring and digital scoring matched on most occasions. The specific intensity threshold settings were for ERb1: 0, X175; 1, o175 and X125; 2, o125 and X80; 3, o80; for ERa: 0, X170; 1, o170 and X120; 2, o120 and X70; 3, o70 and for ERbcx: 0, X177; 1, o177 and X130; 2, o130 and X70; 3, o70. The frequency and intensity scores were then combined into a final score ranging from 0 to 8 (excluding 1). For all sections, three representative areas of invasive tumour were annotated and then subjected to image analysis. Only nuclear ER staining was analysed. When possible, each of the three areas contained at least 1000 nuclei. An average score of 4 or higher was considered as positive ER expression, corresponding to 10% positive cells with weak intensity, a cut-off that has been used in several reports (Mann et al, 2001; Honma et al, 2008) .
Statistics. For descriptive statistics, continuous variables are presented as median (range), while categorical variables are presented as numbers of cases and corresponding percentages. The Pearson's Chi-square test was used to test the hypothesis of equal distribution of ER expression in categorical variables (positive vs negative). For the evaluation of ER status in nodenegative vs node-positive patients, the Pearson's Chi-square test was supplemented by additional logistic regression in order to estimate the odds ratio for the presence of metastasis in different ER status groups. For the testing of distribution of ER expression (positive vs negative) in paired samples, such as primary tumours and their corresponding SLNs, the McNemar test was applied for categorical variables.
Estimation of 10-year survival rates was performed using Kaplan-Meier survival analysis. For the analysis of overall survival, follow-up time was calculated from the date of primary surgery until death of any cause or the date of medical record review, as medical records are directly linked to the national death registry. For the analysis of breast cancer-specific survival, follow-up time was from the date of primary surgery until death caused by breast cancer or the last recorded follow-up visit as documented in medical records at the department of oncology. All patients who died with metastasised breast cancer were considered to have died of the disease. For the analysis of disease-free survival, follow-up time was recorded from the date of primary surgery until the date of any relapse or until the last recorded follow-up visit. The influence of ER status on survival was tested using the log-rank test within the Kaplan-Meier model. As endocrine treatment was assumed to strongly affect survival analysis regarding ER expression, analyses were also adjusted for any endocrine treatment by adding this information as strata into the Kaplan-Meier model. For the comparative analysis of the impact of known risk factors on survival rates and their comparison with the impact of ER receptor status, both uni-and multivariable Cox proportional hazard analyses were performed and results are presented as hazard ratios (HRs) with their 95% confidence intervals (CIs). All statistical computations were performed using IBM SPSS Statistics, Version 21. A P-value of p0.05 was considered statistically significant.
RESULTS
Overall, 340 breast cancer patients operated between January 2001 and December 2006 were included. Of these, 322 tumours were stained and analysed for ERa, 316 for ERb1 and 315 for ERbcx (see Supplementary Figure 1 for representative IHC stainings). Only nuclear staining of ERa, ERb1 and ERbcx was analysed. Overall, 11 patients had no available tumour results of all three ERs, however, they were still included in the cohort since they had ER data from SLNs. Three patients had missing tumour data on ERa and ERb1, three patients on ERa and ERbcx, and two patients on ERb1 and ERbcx. Patient and tumour characteristics are presented in Table 1 . Median follow-up for disease-free and breast cancer-specific survival was 81 months (range 0-148). Median follow-up for overall survival was 115 months (range 2-152). Thirty-six patients had died during the follow-up period, 16 of whom had died of breast cancer. Recurrences were found in 35 patients, sometimes multiple. In total, 10 local, 10 regional and 22 distant relapses were recorded. Ten patients developed contralateral breast cancer during the follow-up period, which was not considered a relapse. The Kaplan-Meier estimate of overall survival for the entire cohort was 83.9%, breast cancer-specific survival 92.1% and disease-free survival 81.6%. Adjuvant endocrine treatment had been given to 268 patients (78.8%) and chemotherapy to 132 patients (39.8%).
Oestrogen receptor status in different age groups and tumour histological grades. A cut-off of 10% was used to distinguish ERpositive from ER-negative tumours. As shown in Figure 1A , the percentage of ERa-positive tumours increased significantly with lower Elston-Ellis histological grade (Po0.001). ERbcx positivity followed a similar pattern but without reaching statistical significance (P ¼ 0.23). ERb1, however, had an equal distribution in all tumour grades (P ¼ 0.771). Patients were divided into four age groups: o40 years (N ¼ 12), 40-54 years (N ¼ 104), 55-64 years (N ¼ 141) and X65 years (N ¼ 81), to study age-related changes in ER positivity. As shown in Figure 1B , there was a significant increase in ERa-positive tumours with increasing age (P ¼ 0.011). There was a similar but non-significant trend for ERbcx positivity (P ¼ 0.062) with increased age category. Again ERb1 showed a different expression pattern, where the positive tumours were equally distributed among all age groups (P ¼ 0.22).
Oestrogen receptor status in primary tumour and synchronous lymph node metastasis. The ER status of primary tumours did not differ significantly compared to their paired synchronous SLN metastases for any of the ERs: ERa (P ¼ 0.33), ERb1 (P ¼ 1.0) and ERbcx (P ¼ 0.13). However, the proportion of ERbcx-positive tumours was higher in node-positive than node-negative patients (P ¼ 0.021; Table 2 ). This was confirmed by logistic regression, which resulted in an odds ratio of 2.54 (95% CI 1.15-5.61) for synchronous SLN metastasis in ERbcx-positive compared to negative cases. No difference in risk of SLN metastasis was seen in patients with ERa-or ERb1-positive primary tumours.
ERb1 expression in the primary tumour strongly affects survival. Ten-year overall survival was significantly lower in women with ERb1-negative tumours (79.7% vs 91.1%, log rank P ¼ 0.009, Figure 2A ) with a HR of 2.48 (95% CI 1.23-5.01). The corresponding figures for patients receiving adjuvant endocrine treatment were 88.7% vs 92.0% and for untreated patients 48.6% vs 92.4% (endocrine treatment-adjusted log rank P ¼ 0.005). No differences were seen when controlling for different types of endocrine treatment, such as tamoxifen or aromatase inhibitors. When primary tumours were stratified according to histological grades, 10-year overall survival was significantly worse for women with ERb1-negative tumours of high grade compared to patients with ERb1-positive high-grade tumours (60% vs 87.8%, log rank P ¼ 0.008). There was no significant survival difference with regard to ERb1 expression within grade 1 and grade 2 tumours. The prognostic potential of ERb1 was also compared within the four age groups described above. Although the youngest age group included too few patients for subgroup analysis, 10-year overall survival was significantly lower in women with ERb1-negative tumours aged 40-54 and 55-64 years than in their ERb1-positive counterparts (80% vs 98.7%, log rank P ¼ 0.001 and 84.7% vs 91.5%, log rank P ¼ 0.042). No significant survival difference in regard to ERb1 status was seen in elderly women (464 years).
We also examined 10-year breast cancer-specific survival. This was significantly lower in women with ERb1-negative tumours (85.4% vs 97.7%, log rank P ¼ 0.011; Figure 2B ) with a HR of 3.44 (95% CI 1.24-9.49). The corresponding figures for patients given adjuvant endocrine treatment were 92.6% vs 93.9% and for untreated patients 59.9% vs 93.4% (endocrine treatment-adjusted log rank P ¼ 0.020). Also for breast cancer-specific survival, no differences were seen when controlling for different types of endocrine treatment. When stratifying by grade, 10-year breast cancer-specific survival was significantly lower in high-grade ERb1-negative tumours compared with high-grade ERb1-positive tumours (58.2% vs 88.2%, log rank P ¼ 0.036). Again, no difference was seen within lower histological grades. Similarly to overall survival, a lower 10-year breast cancer-specific survival was seen in women aged 40-54 years with ERb1-negative tumours than in those with ERb1-positive tumours (76.4% vs 98.1%, log rank P ¼ 0.001). There were no differences in breast cancer-specific survival within the two higher age groups (55-64 and 464 years).
ERa-positive tumours were associated with better breast cancerspecific survival (log rank P ¼ 0.048, Figure 2C ) but not overall survival (log rank P ¼ 0.20). There was no significant association between ERbcx status in the primary tumour and overall or breast cancer-specific survival ( Figure 2D and E) , and no significant patterns were observed when stratifying for histological grades and age groups. None of the analysed ERs affected disease-free survival.
All potential prognostic variables were tested using univariable Cox regression analysis. Significant univariable factors were entered into a multivariable Cox regression model ( Supplementary Table 1 ). As there were few patients in the youngest age group, no 95% CIs could be calculated for this specific group. In the multivariable model, loss of ERb1 was associated with worse prognosis with a HR of 2.40 (95% CI 1. 16-4.94) . Also the loss of PR (HR 3.38, 95% CI 1.76-6.50), older age (465 years) and advanced nodal stage (HR 3.77, 95% CI 1.54-9.19) remained independent of prognostic factors for overall survival. For breast cancer-specific survival, only ERb1 (HR ¼ 3.38, 95% CI 1.09-10.45) and advanced nodal stage (HR ¼ 11.64, 95% CI 2.97-45.63) remained independent prognostic factors.
ER marker combinations affect breast cancer-specific and overall survival. Four combinations of intratumoural ERa and ERb1 expression were created: ERa þ /ERb1 þ (N ¼ 197), ERa þ / ERb1 À (N ¼ 52), ERa À /ERb1 þ (N ¼ 42) and ERa À /ERb1 À (N ¼ 21). Differential 10-year overall survival differed significantly between these four groups with 91.4%, 85.4%, 90.0% and 75.6%, respectively (log rank P ¼ 0.050; Table 3 ). The same pattern was seen for 10-year breast cancer-specific survival rates of 93.9%, 91.0%, 93.6% and 72.1%, respectively (log rank P ¼ 0.009). Interestingly, these differences lost their significance when adjusting for any endocrine treatment, however, significance was retained when adjusted only for ER antagonist-containing postoperative therapy (e.g., tamoxifen; log rank P ¼ 0.032 and 0.031). Corresponding groups were created for ERb1 and ERbcx (N ¼ 210 (ERb1 þ /ERbcx þ ), 23 (ERb1 þ /ERbcx À ), 58 (ERb1 À / ERbcx þ ) and 13 (ERb1 À /ERbcx À )); in these groups, 10-year overall survival was 92.0%, 95.5%, 78.1% and 100%, respectively (log rank P ¼ 0.011). Rates for 10-year breast cancer-specific survival were 95.9%, 92.3%, 80.0% and 100%, respectively (log rank P ¼ 0.001). Adjusting for any endocrine treatment or for ER antagonists retained similar results (log rank P ¼ 0.006 and 0.007 for overall survival and P ¼ 0.002 and 0.003 for breast cancer-specific survival). Similar analyses of combinations of ERa and ERbcx expression did not render any significant associations with survival.
ERbcx expression in SLN lymphocytes is more common in node positivity and affects overall survival. ERb1 and ERbcx positivity of lymphocytes residing in the SLN was seen in 202 out of 285 (70.9%) and 116 out of 292 (39.7%) patients, respectively. In contrast, ERa positivity in these cells was an extremely rare event with only one positive out of 248 cases (0.4%). ERbcx positivity in SLN lymphocytes was more common in node-positive than nodenegative patients (57 out of 125 (45.6%) vs 59 out of 167 (35.3%)), even though this did not reach statistical significance (P ¼ 0.076). This trend was supported by the fact that patients with ERbcx positivity in their SLN had a higher mean number of axillary lymph node metastases (1.4) than those with ERbcx negativity (0.9; P ¼ 0.055). Ten-year overall survival was 93.0% for patients with ERbcx negativity in their SLN lymphocytes, as compared with 84.8% in those with ERbcx SLN lymphocyte positivity (log rank P ¼ 0.053, Figure 2F ). Interestingly, this finding turned significant when adjusting for adjuvant endocrine therapy (log rank P ¼ 0.039). There was no effect of ERbcx SLN lymphocyte status on breast cancer-specific survival or on disease-free survival.
DISCUSSION
Our analysis revealed that ERb1 positivity within the primary tumour is an independent marker for good outcome, more powerful than ERa, which is classically associated with increased survival after adjuvant endocrine therapy. ERb1 expression remained an independent prognostic marker for both overall and breast cancer survival in a multivariable Cox regression model, which strengthens the prognostic value of the receptor. The number of events in our cohort during follow-up period was small due to the generally good prognosis of breast cancer today and considering that included patients were clinically node negative. It has been shown, however, that survival analysis can be reliable with even as little as five events per variable within the Cox regression model. This is especially evident when the association is plausible and hypothesised a priori (Vittinghoff and McCulloch, 2007) . When performing survival analysis in breast cancer while studying ERs it is important with sufficient follow-up due to the risk of late recurrences. The follow-up for breast cancer-specific survival was shorter than for overall survival due to their definitions specified in the Statistics section. However, since any recurrent breast cancer N ¼ 80, 168, and 71) . ERbcx showed a similar trend, however not significant (black; P ¼ 0.23, N ¼ 80, 163, and 69). ERb1 was equally distributed among all three grades (grey; P ¼ 0.771, N ¼ 82, 163, and 68). (B) Patients were divided into four different age groups according to age at diagnosis, o40, 40-54, 55-64, and X65 years. ERa (white) positivity was lowest in the youngest age group and increased with age (P ¼ 0.011, N ¼ 10, 96, 139, and 75). A similar trend was seen with ERbcx (black), however not reaching significance (P ¼ 0.062, N ¼ 11, 93, 135, and 73). ERb1 was equally distributed along all age groups (grey; P ¼ 0.221, N ¼ 11, 93, 137, and 74). Numbers above bars reflect percentage of positive tumours. cases were referred back to the department where this study was performed, it is unlikely that such cases were missed. Thus, followup for breast cancer-specific survival and disease-free survival is probably underestimated. When we stratified patients for endocrine treatment, the survival was similarly high in patients with ERb1-positive tumours. This is somewhat contradicting when The same was seen for breast cancer-specific survival for ERb1-positive tumours (log rank P ¼ 0.011). (C) Breast cancer-specific survival was higher in patients with ERa-positive tumours (log rank P ¼ 0.048). (D) Breast cancer-specific survival did not differ between patients with ERbcx-positive or -negative tumours (log rank P ¼ 0.73). (E) There was a trend towards better overall survival in patients with ERbcx-negative tumours; however, this did not reach statistical significance (log rank P ¼ 0.18). (F) Patients with ERbcx-negative lymphocytes in the sentinel node showed a non-significant trend towards better overall survival (log rank P ¼ 0.053). Numbers at risk at each time point are given below each subfigure. compared with the results of Honma et al (2008) , where the increase in survival was only seen in ERb1-positive patients treated with tamoxifen for 42 years. Our group of endocrine-treated women, however, received tamoxifen and/or aromatase inhibitors usually for 5 years, which may perhaps explain the differences in survival. When we examined survival regarding the co-expression of ERa and ERb1, patients who were either double or single positive had an equally good prognosis, meaning that ERb1 is a potential biomarker for distinguishing between patients with good or bad prognosis in ERa-negative tumours, generally considered as a group of patients with poor prognosis. ERb1 and ERbcx coexpression was associated with survival in a similar manner, again the lowest survival was seen in the ERb1-negative tumours. Intriguingly, these tumours were also ERbcx-positive. ERbcx is thought to affect ER function through negative regulation by heterodimerisation, mainly with ERa, causing degradation of the receptor complex and therefore a decrease of ERa level (Zhao et al, 2007) . This mechanism may result in a completely ER-negative tumour (ERa À and ERb1 À ). Therefore, this tumour could be less sensitive to endocrine therapy and perhaps more responsive to chemotherapy. As described earlier it is important to remember that the stratification and subgroup analysis of the co-expression data is performed on a small cohort and with few events, which merits caution when interpreting these results. However, we believe that the findings are both clinically and biologically relevant, but need further validation.
ERb1 seems to be present in tumours in patients from all age groups, whereas ERa expression is usually less common in younger women. Most interestingly, the negative prognostic significance of the lack of ERb1 expression in the primary tumour is particularly strong in younger age groups and in tumours of high histological grades. Therefore, ERb should be considered a valuable prognostic biomarker and perhaps a therapeutical target in younger women in whom triple-negative breast cancer (absence of ERa, PR and HER2) is more common. Tamoxifen and other current endocrine therapies such as aromatase inhibitors, however, are designed to treat ERaexpressing cancers and might not be the optimal therapy for targeting ERb1. Our data suggest that the examination of ERb1 status should have an additional prognostic value during routine pathological examination of breast cancer, but not as a biomarker for endocrine responsiveness within ERa-negative cases as described elsewhere (Gruvberger-Saal et al, 2007; Honma et al, 2008) . Further research is needed to identify the ideal ERb1-targeting therapy and to validate our findings.
Although several prospective investigations on ERb isoforms in breast cancer have been performed, the potential association with clinicopathological parameters and survival remains unclear. The expression of the different ERb isoforms is a result of alternative splicing at the C-terminus; consequently, antibodies raised against the N-terminus will inevitably quantitate the total ERb level. This may cause a false view of the isoform-specific expression. In our study, we analysed ERb1 expression with a widely cited, wellvalidated C-terminal monoclonal antibody Carder et al, 2005; Weitsman et al, 2006; Novelli et al, 2008) . As mentioned, ERb has been described as an anti-proliferative, tumour-suppressive receptor within breast cancer cells in vitro (Hartman et al, 2009 ). Consequently, it has been hypothesised that ERb should be downregulated during breast cancer progression (Roger et al, 2001) . However, paired primary tumours and corresponding metastatic lesions are extremely scarce materials and the hypothesis is thus hard to prove. Often, the presence of locoregional lymph node metastases are used as a surrogate parameter, as they are one of the strongest risk factors for breast cancer death and distant metastases (Fisher et al, 1983; Andersson et al, 2010) . In a study on 50 patients, Gschwantler-Kaulich et al (2011) observed that compared to the primary tumour, there was a reduction in both ERa and ERb levels in axillary lymph node metastases. In our analysis, ER status differed between primary tumour and corresponding lymph node metastases in several patients, even though we could not identify any changes in the overall pattern of ER status. This discrepancy is probably explained by the fact that Gschwantler-Kaulich et al used TMAs with 1 mm cores while our analysis was based on whole sections. It is evident that intratumoural ER levels are heterogeneously expressed, hence, IHC on TMAs may not be an optimal method for ER assessment of breast cancer specimens. Furthermore, to reduce variation and bias in our study, all IHC stainings were assessed by computer-assisted image analysis (see Materials and Methods section) in a blinded manner. This method, if correctly performed, is able to reduce both intra-and interobserver variation in biomarker assessments (Krecsák et al, 2011) . Our analysis further showed that patients with ERbcxpositive primary tumours had an increased risk of lymph node metastasis. Nonetheless, the ER status of the corresponding lymph node metastasis did not correlate to outcome.
Oestrogen receptors, expressed in lymphocytes, are important in the maturation of B cells and play a crucial role in the peripheral immune system; this effect is mediated by both ERa and ERb (Shim et al, 2006; Hill et al, 2011) . Within the stroma of mammary gland and tumour adjacent tissue, ERb is the predominating ER . In the majority of our patients, we observed that lymphocytes within the SLNs express ERb1 (70.9%) while a minority expressed ERbcx (39.4%) and o1% expressed ERa. We found that lymphocytes within lymph nodes containing metastatic Abbreviations: BCSS ¼ breast cancer-specific survival; ER ¼ oestrogen receptor; OS ¼ overall survival. The highest 10-year OS/BCSS was seen in ERa þ /ERb1 þ tumours. Either ERa þ / ERb1 À or ERa À /ERb1 þ was also associated with better prognosis, compared to double negative tumours (ERa À /ERb1 À that had the worst prognosis for both OS and BCSS. For ERb and ERbcx co-expression, the worst 10-year OS/BCSS was seen in patients with ERb1 À /ERbcx þ tumours, compared to ERb1 þ /ERbcx þ , ERb1 þ /ERbcx À and ERb1 À / ERbcx À . No significant differences in 10-year OS or BCSS were seen when comparing the co-expression of ERa and ERbcx. *Po0.05.
breast cancer cells express higher levels of ERbcx. In patients treated with endocrine therapy, ERbcx-positive SLN lymphocytes indicated a poor prognosis and were furthermore associated with shorter 10-year overall survival. Our data imply that ERbcx within SLN lymphocytes may govern a yet unknown mechanism of breast cancer progression. Since the lymphocytes expressed little ERa, the tumourigenic function could perhaps be mediated through heterodimerisation and inhibition of ERb1. In summary, this study indicates that ERb1 and the ERb splice variant ERbcx have several important roles during breast tumourigenesis. In the primary tumour, ERb1 was associated with good outcome and probably has a tumour-suppressive function. ERbcx, however, seems to play the most important role in regional lymph nodes where its presence in lymphocytes correlated to overall survival in breast cancer patients through an as yet unknown mechanism. The analysis of ERb1 and ERbcx by IHC provides useful clinical information, especially for younger women and tumours of high histological grade. Further research is needed to understand how to pharmaceutically target the individual ER subtypes in breast cancer patients.
